참고문헌 (28)

1. Clin Rev Bone Miner Metab B Lecka-Czernik 11 49 2013 10.1007/s12018-012-9129-7 Lecka-Czernik B (2013) Safety of anti-diabetic therapies on bone. Clin Rev Bone Miner Metab 11:49-58 

   상세보기

2. Osteoporos Int SL Ferrari 29 2585 2018 10.1007/s00198-018-4650-2 Ferrari SL, Abrahamsen B, Napoli N et al (2018) Diagnosis and management of bone fragility in diabetes: an emerging challenge. Osteoporos Int 29:2585-2596 

   상세보기

3. Nat Rev Endocrinol N Napoli 13 208 2017 10.1038/nrendo.2016.153 Napoli N, Chandran M, Pierroz DD, Abrahamsen B, Schwartz AV, Ferrari SL, Bone IOF, Diabetes Working G (2017) Mechanisms of diabetes mellitus-induced bone fragility. Nat Rev Endocrinol 13:208-219 

   상세보기

4. J Bone Miner Res N Napoli 33 63 2018 10.1002/jbmr.3287 Napoli N, Schwartz AV, Schafer AL, Vittinghoff E, Cawthon PM, Parimi N, Orwoll E, Strotmeyer ES, Hoffman AR, Barrett-Connor E, Black DM, for the Osteoporotic Fractures in Men (MrOS) Study Research Group (2018) Vertebral fracture risk in diabetic elderly men: the MrOS study. J Bone Miner Res 33:63-69 

   상세보기

5. Int J Endocrinol N Napoli 2014 690783 2014 Napoli N, Strollo R, Paladini A, Briganti SI, Pozzilli P, Epstein S (2014) The alliance of mesenchymal stem cells, bone, and diabetes. Int J Endocrinol 2014:690783 

6. J Clin Endocrinol Metab N Napoli 104 3303 2019 10.1210/jc.2018-02539 Napoli N, Conte C, Pedone C, Strotmeyer ES, Barbour KE, Black DM, Samelson EJ, Schwartz AV (2019) Effect of insulin resistance on BMD and fracture risk in older adults. J Clin Endocrinol Metab 104:3303-3310 

   상세보기

7. Br J Pharmacol CE Quinn 153 636 2008 10.1038/sj.bjp.0707452 Quinn CE, Hamilton PK, Lockhart CJ, McVeigh GE (2008) Thiazolidinediones: effects on insulin resistance and the cardiovascular system. Br J Pharmacol 153:636-645 

   상세보기

8. Cell K Fulzele 142 309 2010 10.1016/j.cell.2010.06.002 Fulzele K, Riddle RC, DiGirolamo DJ et al (2010) Insulin receptor signaling in osteoblasts regulates postnatal bone acquisition and body composition. Cell 142:309-319 

   상세보기

9. Diabetes Metab Res Rev EJ Gallagher 30 191 2014 10.1002/dmrr.2466 Gallagher EJ, Sun H, Kornhauser C, Tobin-Hess A, Epstein S, Yakar S, LeRoith D (2014) The effect of dipeptidyl peptidase-IV inhibition on bone in a mouse model of type 2 diabetes. Diabetes Metab Res Rev 30:191-200 

   상세보기

10. Osteoporos Int A Palermo 26 2073 2015 10.1007/s00198-015-3123-0 Palermo A, D'Onofrio L, Eastell R, Schwartz AV, Pozzilli P, Napoli N (2015) Oral anti-diabetic drugs and fracture risk, cut to the bone: safe or dangerous? A narrative review. Osteoporos Int 26:2073-2089 

    상세보기

11. Diabetes Res Clin Pract JM Gamble 136 159 2018 10.1016/j.diabres.2017.12.008 Gamble JM, Donnan JR, Chibrikov E, Twells LK, Midodzi WK, Majumdar SR (2018) The risk of fragility fractures in new users of dipeptidyl peptidase-4 inhibitors compared to sulfonylureas and other anti-diabetic drugs: a cohort study. Diabetes Res Clin Pract 136:159-167 

    상세보기

12. Diabetes Care M Monami 34 2474 2011 10.2337/dc11-1099 Monami M, Dicembrini I, Antenore A, Mannucci E (2011) Dipeptidyl peptidase-4 inhibitors and bone fractures: a meta-analysis of randomized clinical trials. Diabetes Care 34:2474-2476 

    상세보기

13. J Korean Med Sci M Ustulin 34 e224 2019 10.3346/jkms.2019.34.e224 Ustulin M, Park SY, Choi H, Chon S, Woo JT, Rhee SY (2019) Effect of dipeptidyl peptidase-4 inhibitors on the risk of bone fractures in a Korean population. J Korean Med Sci 34:e224 

    상세보기

14. Diabetes Res Clin Pract NH Cho 106 Suppl 2 S282 2014 10.1016/S0168-8227(14)70730-2 Cho NH (2014) Diabetes burden and prevention in Korea and the Western Pacific region. Diabetes Res Clin Pract 106(Suppl 2):S282-S287 

    상세보기

15. Korean J Intern Med JH Lee 35 1432 2020 10.3904/kjim.2018.223 Lee JH, Kim JH, Hong AR, Kim SW, Shin CS (2020) Optimal body mass index for minimizing the risk for osteoporosis and type 2 diabetes. Korean J Intern Med 35:1432-1442 

    상세보기

16. Yonsei Med J EJ Park 55 1049 2014 10.3349/ymj.2014.55.4.1049 Park EJ, Joo IW, Jang MJ, Kim YT, Oh K, Oh HJ (2014) Prevalence of osteoporosis in the Korean population based on Korea National Health and Nutrition Examination Survey (KNHANES), 2008-2011. Yonsei Med J 55:1049-1057 

    상세보기

17. J Korean Med Sci JA Kim 32 718 2017 10.3346/jkms.2017.32.5.718 Kim JA, Yoon S, Kim LY, Kim DS (2017) Towards actualizing the value potential of Korea health insurance review and assessment (HIRA) data as a resource for Health Research: strengths, limitations, applications, and strategies for optimal use of HIRA data. J Korean Med Sci 32:718-728 

    상세보기

18. Value Health VS Catalan 3 417 2000 10.1046/j.1524-4733.2000.36006.x Catalan VS, LeLorier J (2000) Predictors of long-term persistence on statins in a subsidized clinical population. Value Health 3:417-426 

    상세보기

19. Med Care H Quan 43 1130 2005 10.1097/01.mlr.0000182534.19832.83 Quan H, Sundararajan V, Halfon P, Fong A, Burnand B, Luthi JC, Saunders LD, Beck CA, Feasby TE, Ghali WA (2005) Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care 43:1130-1139 

    상세보기

20. J Chronic Dis ME Charlson 40 373 1987 10.1016/0021-9681(87)90171-8 Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40:373-383 

    상세보기

21. Stat Med PC Austin 33 1242 2014 10.1002/sim.5984 Austin PC (2014) The use of propensity score methods with survival or time-to-event outcomes: reporting measures of effect similar to those used in randomized experiments. Stat Med 33:1242-1258 

    상세보기

22. Multivar Behav Res PC Austin 46 399 2011 10.1080/00273171.2011.568786 Austin PC (2011) An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivar Behav Res 46:399-424 

    상세보기

23. Osteoporos Int HJ Choi 27 2709 2016 10.1007/s00198-016-3595-6 Choi HJ, Park C, Lee YK, Ha YC, Jang S, Shin CS (2016) Risk of fractures and diabetes medications: a nationwide cohort study. Osteoporos Int 27:2709-2715 

    상세보기

24. Sci Rep J Fu 6 29104 2016 10.1038/srep29104 Fu J, Zhu J, Hao Y, Guo C, Zhou Z (2016) Dipeptidyl peptidase-4 inhibitors and fracture risk: an updated meta-analysis of randomized clinical trials. Sci Rep 6:29104 

    상세보기

25. Br J Clin Pharmacol WH Hou 84 2029 2018 10.1111/bcp.13636 Hou WH, Chang KC, Li CY, Ou HT (2018) Dipeptidyl peptidase-4 inhibitor use is associated with decreased risk of fracture in patients with type 2 diabetes: a population-based cohort study. Br J Clin Pharmacol 84:2029-2039 

    상세보기

26. J Clin Endocrinol Metab DH Solomon 94 2792 2009 10.1210/jc.2008-2157 Solomon DH, Cadarette SM, Choudhry NK, Canning C, Levin R, Sturmer T (2009) A cohort study of thiazolidinediones and fractures in older adults with diabetes. J Clin Endocrinol Metab 94:2792-2798 

    상세보기

27. Bone ZN Zhu 68 115 2014 10.1016/j.bone.2014.08.010 Zhu ZN, Jiang YF, Ding T (2014) Risk of fracture with thiazolidinediones: an updated meta-analysis of randomized clinical trials. Bone 68:115-123 

    상세보기

28. Diabetologia N Napoli 57 2057 2014 10.1007/s00125-014-3289-6 Napoli N, Strotmeyer ES, Ensrud KE, Sellmeyer DE, Bauer DC, Hoffman AR, Dam TTL, Barrett-Connor E, Palermo L, Orwoll ES, Cummings SR, Black DM, Schwartz AV (2014) Fracture risk in diabetic elderly men: the MrOS study. Diabetologia 57:2057-2065 

    상세보기

활용도 Top5 논문

더보기

해당 논문의 주제분야에서 활용도가 높은 상위 5개 콘텐츠를 보여줍니다.
더보기 버튼을 클릭하시면 더 많은 관련자료를 살펴볼 수 있습니다.